Enveric Biosciences, Inc. 8-K Filing
Ticker: ENVB · Form: 8-K · Filed: Dec 12, 2025 · CIK: 890821
| Field | Detail |
|---|---|
| Company | Enveric Biosciences, Inc. (ENVB) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.01, $36.00, $10.98, $7.05, $0.125 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Enveric Biosciences, Inc. (ticker: ENVB) to the SEC on Dec 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar); $36.00 (ptember 2025, having exercise prices of $36.00 and $10.98 per share, respectively (col); $10.98 (5, having exercise prices of $36.00 and $10.98 per share, respectively (collectively,); $7.05 (Warrants at a reduced exercise price of $7.05 per share and pay a purchase price of $); $0.125 (5 per share and pay a purchase price of $0.125 per share in consideration for the Comp).
How long is this filing?
Enveric Biosciences, Inc.'s 8-K filing is 8 pages with approximately 2,549 words. Estimated reading time is 10 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 2,549 words · 10 min read · ~8 pages · Grade level 13.7 · Accepted 2025-12-12 17:10:38
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar
- $36.00 — ptember 2025, having exercise prices of $36.00 and $10.98 per share, respectively (col
- $10.98 — 5, having exercise prices of $36.00 and $10.98 per share, respectively (collectively,
- $7.05 — Warrants at a reduced exercise price of $7.05 per share and pay a purchase price of $
- $0.125 — 5 per share and pay a purchase price of $0.125 per share in consideration for the Comp
- $3.1 million — gregate gross proceeds of approximately $3.1 million from the exercise of the Existing Warra
- $35,000 — and the issuance of the New Warrants of $35,000 for its non-accountable expenses, up to
- $50,000 — for its non-accountable expenses, up to $50,000 for its accountable expenses and $15,95
- $15,950 — 50,000 for its accountable expenses and $15,950 for its clearing costs. The Company has
- $9.125 — ts will have an exercise price equal to $9.125 per share (125% of the offering price).
Filing Documents
- form8-k.htm (8-K) — 67KB
- ex4-1.htm (EX-4.1) — 132KB
- ex4-2.htm (EX-4.2) — 132KB
- ex4-3.htm (EX-4.3) — 131KB
- ex10-1.htm (EX-10.1) — 63KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-2.htm (EX-99.2) — 15KB
- 0001493152-25-027541.txt ( ) — 834KB
- envb-20251211.xsd (EX-101.SCH) — 3KB
- envb-20251211_lab.xml (EX-101.LAB) — 33KB
- envb-20251211_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2025 ENVERIC BIOSCIENCES, INC. By: /s/ Joseph Tucker Joseph Tucker, Ph.D. Chief Executive Officer